Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal distension07.01.04.0010.007505%
Abdominal pain07.01.05.0020.020848%
Abdominal tenderness07.01.05.0040.002780%-
Accommodation disorder06.02.04.001---
Acidosis14.01.03.0020.004170%
Acidosis hyperchloraemic14.01.01.0070.002780%-
Acne23.02.01.001---
Acute hepatic failure09.01.03.0010.045032%-
Acute psychosis19.03.01.0010.002780%-
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.006949%
Agranulocytosis01.02.03.001---
Alanine aminotransferase increased13.03.04.005--
Altered state of consciousness17.02.04.001; 19.07.01.0030.012509%-
Anaphylactic reaction10.01.07.001; 24.06.03.0060.006949%
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.008339%-
Aortic aneurysm24.02.03.0010.002780%-
Aplasia pure red cell01.03.03.001; 10.02.01.0030.005560%-
Aplastic anaemia01.03.03.002---
Arthralgia15.01.02.0010.016679%
Ascites02.05.04.002; 07.07.01.001; 09.01.05.0030.014455%
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.026964%-
Ataxia08.01.02.004; 17.02.02.0010.004170%
Atrophy08.03.04.001---
Azotaemia20.01.01.0010.004170%-
Bilirubinuria20.02.01.015---
Blindness06.02.10.003; 17.17.01.0030.002780%-
Blister12.01.06.002; 23.03.01.0010.004170%-
Blood bilirubin increased13.03.04.018--
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene